Holen Sie sich die Stockscreener-App
4.19
1.70%
0.07
Handel nachbörslich:
4.22
0.03
+0.72%
Schlusskurs vom Vortag:
$4.12
Offen:
$4.21
24-Stunden-Volumen:
4.02M
Relative Volume:
1.23
Marktkapitalisierung:
$794.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-196.48M
KGV:
-3.4463
EPS:
-1.2158
Netto-Cashflow:
$-183.16M
1W Leistung:
+15.11%
1M Leistung:
-15.01%
6M Leistung:
-23.82%
1J Leistung:
+34.73%
1-Tages-Spanne:
$4.105
$4.265
1-Wochen-Bereich:
$3.735
$4.38
52-Wochen-Spanne:
$2.54
$7.18
Annexon Inc Stock (ANNX) Company Profile
Firmenname
Annexon Inc
Sektor
Branche
Telefon
(650) 822-5500
Adresse
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
4.19 | 690.07M | 0 | -196.48M | -183.16M | -1.2158 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-30 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-05-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | BTIG Research | Buy |
| 2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | BofA Securities | Buy |
| 2020-08-18 | Eingeleitet | Cowen | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Annexon Inc Aktie (ANNX) Neueste Nachrichten
Annexon Price Target Raised to $15.00/Share From $14.00 by JP Morgan - Moomoo
ANNX Maintained by JP Morgan -- Price Target Raised to $15.00 - GuruFocus
JPMorgan raises Annexon Biosciences price target on trial data By Investing.com - Investing.com Canada
Insider Spends US$100k Buying More Shares In Annexon - Simply Wall Street
Annexon: Preserving Patient Function Is The Real Investment Opportunity (NASDAQ:ANNX) - Seeking Alpha
Annexon (ANNX) President and CEO Douglas Love Buys 26,065 Shares - GuruFocus
After buying shares at a $3.83 average, Annexon (ANNX) CEO Love Douglas holds 390,476 shares. - Stock Titan
Annexon, Inc. (ANNX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Annexon presents vonaprument data at retina meeting By Investing.com - Investing.com India
Annexon presents vonaprument data at retina meeting - Investing.com
More than 8 million people have an eye disease that can cause blindness. Annexon will present trial findings. - Stock Titan
Annexon (ANNX) Ticks Up 1.44% to $4.23, Holding Firmly Above $4.02 SupportDealer Delta - dars.gov.et
After +5.47% Gain, Is Annexon (ANNX) Still a Value Play? 2026-09-17Strong Buy Stocks - dars.gov.et
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com Nigeria
ANNX: Vonaprument's phase III trial in GA shows promise for vision preservation and broad market impact - TradingView
ANNX: Phase III GA study shows strong vision preservation, with high compliance and dual primary endpoints - TradingView
ANNX: Phase III programs in GBS and GA advance toward key data and regulatory milestones, with strong differentiation - TradingView
Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com India
Annexon secures $200 million credit facility from Oxford Finance - scanx.trade
Annexon to Participate in Upcoming September Investor Conferences - Investing News Network
ANNX Maintained by JP Morgan -- Price Target Raised to $14.00 - GuruFocus
ANNEXON, INC. : JP MORGAN RAISES TARGET PRICE TO $14 FROM $10 - Moomoo
What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders - Yahoo Finance
Annexon (ANNX): Pipeline Momentum Is Building, but Cash Discipline Still Runs the Story - AlphaStreet
Annexon (ANNX) Quarterly Figures: The Available Earnings Metric Delivers a Beat in the Current Update; Share Response: The Stock Loses 4.55% in the Current UpdateMargin Guidance - vinanet.vn
Annexon (ANNX) Q2 2026 Earnings Call Transcript - AOL.com
Annexon, Inc. Stock 12‑Month Price Target Raised to $15.71, Implies 198% Upside - TradingView
Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4) - marketscreener.com
Bank of America Corp DE Has $23.60 Million Stock Holdings in Annexon, Inc. $ANNX - MarketBeat
Annexon Inc (ANNX) Stock News Today - TradingKey
At $5.29, Annexon grants new employees options vesting over four years - Stock Titan
Annexon (ANNX) Adds Dual Primary Endpoint in Phase 3 Trial, Refl - GuruFocus
Annexon (ANNX) Earnings Call zu Q2 2026: ARCHER II erweitert, BLA-Einreichung im Zeitplan - TradingKey
Annexon (ANNX) Q2 2026 Earnings Call: ARCHER II Expanded, BLA Filing on Track - TradingKey
What is HC Wainwright's Estimate for Annexon Q3 Earnings? - MarketBeat
Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II TrialWhat's Changed - Sahm
Annexon (NASDAQ:ANNX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
ANNX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
State Street Corp Boosts Annexon Inc (ANNX) Stake by 42% in June Transaction - GuruFocus
A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $8 to $27 - Moomoo
Insider for ANNX (ANNX) plans sale of 2,000 shares after option exercise - Stock Titan
Annexon (ANNX), What Is Behind Its Latest Update? - Yahoo Finance
ANNX Upgraded by Citizens -- Rating Changed to Market Perform - GuruFocus
Annexon (NASDAQ:ANNX) Upgraded at Citizens Jmp - MarketBeat
BofA Securities Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Citizens upgrades Annexon stock rating on trial endpoint changes - Investing.com
Annexon Announces $55.3 Million Net Loss in Q2 2026 Financial Results - Kalkine Media
Form 8K Annexon Inc For: 12 August By Investing.com - Investing.com Nigeria
Annexon, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Annexon (NASDAQ: ANNX) reports $99.5M H1 2026 loss and secures new $200M debt facility - Stock Titan
Finanzdaten der Annexon Inc-Aktie (ANNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):